← Back to Search

[18F]SF12051 Imaging for Healthy Subjects

Phase 1
Waitlist Available
Led By Robert B Innis, M.D.
Research Sponsored by National Institute of Mental Health (NIMH)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18 years or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

Study Summary

This trial will test whether a new radiotracer can make TSPO, a protein that appears in higher numbers when inflammation affects nerve cells, appear on PET scans. Healthy people aged 18 and older are eligible. The trial requires 2-4 visits to the clinic.

Who is the study for?
Healthy adults over 18 can join this trial. They must be in good health based on medical exams, blood tests, and heart function tests. Participants need to have a specific TSPO genotype and agree to lifestyle considerations for the study duration. Pregnant or breastfeeding individuals, those with significant medical conditions or metal objects in their wrists, and anyone unable to lie flat for scans are excluded.Check my eligibility
What is being tested?
[18F]SF12051 is being tested as a new radiotracer that could highlight the TSPO protein on PET scans of the brain and body. This could help measure inflammation related to various diseases. The study involves multiple clinic visits with PET scans of either the whole body or just the head, along with an MRI scan for some participants.See study design
What are the potential side effects?
Potential side effects may include discomfort from lying still during scanning procedures, reactions at injection sites where catheters are placed (like bruising), exposure to radiation from PET scans which is within safe limits but cumulative if participating in other studies too.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate the brain uptake of [18F]SF12051 in healthy volunteers
Secondary outcome measures
Study retest variability and reliability of [18F]SF12051

Trial Design

1Treatment groups
Experimental Treatment
Group I: Only one armExperimental Treatment1 Intervention
All subjects receive the same tests
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-SF12051
2023
Completed Phase 1
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Institute of Mental Health (NIMH)Lead Sponsor
2,783 Previous Clinical Trials
2,689,117 Total Patients Enrolled
Robert B Innis, M.D.Principal InvestigatorNational Institute of Mental Health (NIMH)
27 Previous Clinical Trials
1,294 Total Patients Enrolled

Media Library

Only one arm Clinical Trial Eligibility Overview. Trial Name: NCT05564429 — Phase 1
Healthy Subjects Research Study Groups: Only one arm
Healthy Subjects Clinical Trial 2023: Only one arm Highlights & Side Effects. Trial Name: NCT05564429 — Phase 1
Only one arm 2023 Treatment Timeline for Medical Study. Trial Name: NCT05564429 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could people who are under 25 years old take part in this experiment?

"Eligible patients for this trial must be aged 18 to 99. In contrast, 52 clinical trials target a pediatric population while 390 trials focus on adults aged 65 and older."

Answered by AI

Are there still volunteer opportunities available for this research?

"The most recent information available on clinicaltrials.gov suggests that this trial is currently looking for patients. The study was first posted on November 14th, 2020 and was last updated on November 8th, 2020."

Answered by AI

Are there any risks associated with this treatment plan?

"This is a Phase 1 trial, so there is only preliminary data to support the safety of this treatment. Our team at Power rates it as a 1."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
[18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects
2023. "[18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05564429.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top